QR Pharma, Inc. to Present Corporate Update at 23rd Annual
BioCentury NewsMakers Conference
–One of Fourteen Private Companies Selected to Present–
Berwyn, PA, September 9, 2016 — QR Pharma, Inc., a privately held Phase 2 biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative diseases, today announced that Maria Maccecchini, Ph.D., President and CEO, will present a corporate update at the 23rd Annual BioCentury NewsMakers in the Biotech Industry Conference at 3:00 PM ET on September 9, 2016 at the Millennium Broadway Hotel & Conference Center in New York, NY. Dr. Maccecchini will also be participating in 1×1 meetings with investors and industry executives.
About QR Pharma, Inc.
Headquartered in Berwyn, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment in neurological disorders.
QR is currently developing Posiphen as a disease-modifying drug for acute as well as chronic neurodegeneration and BNC for advanced Alzheimer’s disease. For more information on QR Pharma, please visit the company’s website, www.qrpharma.com
Contact: Maria Maccecchini
Tel: 610-727 3710
Fax: 610 727 4001